Lexaria Bioscience Corp.
LEXX · NASDAQ
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | -5.4% | 119% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 98.5% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,137.6% | -1,579.7% | -1,444.9% | -2,621.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,177.6% | -1,559.3% | -1,470% | -2,600.9% |
| EPS Diluted | -0.21 | -0.15 | -0.16 | -0.17 |
| % Growth | -40% | 6.3% | 5.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |